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Background: In patients with locally advanced or recurrent pelvic malignancies, total pelvic exenteration (TPE) may
be necessary for curative treatment. Despite improvements in mortality rates since TPE was first described,
morbidity rates remain high due to the extensive resection and the aggressiveness of these tumors. We have
studied the outcomes of TPE surgery performed at our institution.
Methods: Fifty-three patients with various pelvic pathologies underwent TPE between 2004 and 2010. Patients
were divided into two groups based on pathology: colorectal (n= 36) versus non-colorectal (n = 17) malignancies.
Demographics, operative reports, pathology reports, periprocedural events, and outcomes were analyzed.
Comparison of the two groups was performed using student’s t-test and Fisher’s exact test. Survival curves were
constructed using the Kaplan–Meier method and compared using the log rank test.
Results: The colorectal and non-colorectal groups were similar in demographics, operative times, length of stay,
estimated blood loss, and rates of preoperative and intraoperative radiation use. Chemotherapy use was increased
in the colorectal group compared with the non-colorectal group (55.6% vs. 23.5%, P = 0.04). Complication rates
were similar: 86% in the colorectal group and 76% in the non-colorectal group. In the colorectal group, 27.8% of
patients developed perineal abscesses, whereas no patients developed these complications in the non-colorectal
group (P = 0.02). No survival difference was seen in primary versus recurrent colorectal tumors; however, within the
colorectal group there was a survival advantage when comparing R0 resection to R1 and R2 resection combined.
Median survival rates were 27.3 months for R0 resection and 10.7 months for R1 and R2 resection combined. The
median survival was 21.4 months for the colorectal group and 6.9 months for the non-colorectal group (P = 0.002).
Conclusions: Patients undergoing TPE for colorectal tumors have improved survival when compared with patients
undergoing exenteration for pelvic malignancies of other origins. Within the colorectal group, the extent of
resection demonstrated a significant survival benefit of an R0 resection compared with R1 and R2 resections.
Despite TPE carrying a high morbidity rate, mortality rates have improved and careful patient selection can
optimize outcomes.
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In patients with advanced primary or recurrent pelvic
malignancies without metastatic disease, extensive ag-
gressive surgery such as total pelvic exenteration (TPE)
may be necessary for curative treatment. TPE can also
be considered in the setting of suspected disease recur-
rence, complications due to radiation treatment, and for
palliative treatment of metastatic disease with severe pel-
vic symptomatology. Although initially performed at the
Ellis Fischel Cancer Center in the 1940s, this highly
morbid procedure was originally described by Brunsch-
wig for patients with advanced pelvic malignancies in
1948 [1]. It involves a complete extirpation of the anal
canal, rectum and distal colon, the bladder and lower
ureters, the internal reproductive organs, draining lymph
nodes, and the adjacent pelvic peritoneum. After re-
moval of the bladder, methods of urinary diversion, such
as the ileal conduit described by Bricker, [2] the double-
barreled wet colostomy, [3] or neobladder construction
are utilized. TPE has been performed in patients who
have had primary and recurrent malignancies in the cer-
vix, endometrium, vulva, vagina, prostate, bladder, rec-
tum, and who have had pelvic sarcomas.
Early TPE series reported mortality rates of up to 30%
[4-11]. More recent series have demonstrated improved
mortality rates between 0 and 10% [12-17]. Despite a de-
crease in mortality, morbidity has remained high among
these patients, with complication rates between 13 and
78% in patients undergoing TPE for colorectal malignan-
cies [4,10-16,18-23]. Careful patient selection is impera-
tive to optimize outcomes in patients undergoing this
extensive surgical procedure for advanced and recurrent
pelvic malignancies.
Our study describes the results of a single institution
experience with TPE over a 6-year period, with a
detailed examination of operative related complications.
In addition, morbidity, mortality, and survival were eval-
uated for patients undergoing TPE for colorectal and
non-colorectal malignancies and their results compared.
Methods
Fifty-three patients underwent TPE between January
2004 and August 2010 at the Arthur G. James Cancer
Hospital by surgeons from the divisions of surgical on-
cology, urology, and gynecologic oncology. This proced-
ure was indicated for patients with locally advanced
primary, recurrent, or suspected recurrent pelvic malig-
nancies. After obtaining permission from The Ohio State
University Institutional Review Board, the medical re-
cords of these patients were retrospectively reviewed.
TPE included resection of the distal sigmoid colon, rec-
tum, anal canal, distal ureters, bladder, internal reproduct-
ive organs, and pelvic lymph nodes. Urinary diversion was
achieved by construction of an ileal conduit [2] or adouble-barreled wet colostomy [3,24]. In patients without
bilateral abdominal wall violation and with patent inferior
epigastric arteries, rectus abdominus myocutaneous flaps
were used for pelvic reconstruction and closure. Preopera-
tive imaging including computed tomography (CT) scans
and/or positron emission tomography (PET) scans were
used to assess resectability of the tumor and to determine
if the malignancy was confined to the pelvis. Clinical signs
of ureteral or bowel obstruction were not contraindica-
tions for TPE. TPE was not performed, however, if
patients were too ill to tolerate an extensive surgery, dis-
ease was technically unresectable due to invasion of neu-
rovascular structures, or if patients had widely metastatic
asymptomatic disease. Palliative TPE was performed for
patients with locally advanced unresectable disease or
metastatic disease combined with significant pelvic symp-
tomatology, including severe pelvic or perineal pain, ob-
struction, fistulas, bleeding, or non-healing perineal
wounds causing significant morbidity and affecting quality
of life. Patients were made thoroughly aware of the poten-
tial morbidities associated with the procedure and were
willing to accept these risks in exchange for potential im-
provement in their pelvic symptoms.
TPE patients were divided into two groups, those who
underwent TPE for colorectal cancer and those who
underwent the surgery for non-colorectal cancer. Demo-
graphics including age, gender, and comorbidities were
compared between the two groups. Preoperative treat-
ment data including neoadjuvant chemotherapy and ra-
diation were analyzed. Operative reports were reviewed
to assess operative time, estimated blood loss, and ad-
ministration of intraoperative radiation therapy. Intrao-
perative radiation therapy was indicated when there was
concern of pelvic sidewall or sacral invasion by the
tumor after gross tumor resection. It was contraindi-
cated in patients who had already received a prohibitive
dose of preoperative radiation to the pelvis, as deter-
mined by the consultant radiation oncologist. Peri-
procedural events, outcomes, and survival data were
investigated for each of the two groups.
Tumors were categorized as primary, recurrent, or
suspected recurrence. Suspected recurrences consisted
of patients who had radiographic evidence of tumor re-
currence with no pathological evidence of viable tumor
on examination of the specimen. Operative and path-
ology reports of all patients were analyzed to determine
the completeness of tumor resection. Completeness of
resection was divided into R0 (complete resection of
tumor), R1 (microscopic tumor in specimen margin), R2
(macroscopically incomplete resection), and suspected
recurrence/complication. Postoperative and follow-up
data collected included length of stay, morbidity, and
mortality. Survival was calculated as the time from TPE
to the time of death.
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Continuous variables were compared by student’s t-test
for comparison of independent groups and a non-
parametric alternative (Wilcoxon rank sum test) for data
not distributed normally. Contingency table analysis
(chi-square and Fisher’s exact test) was used, when ap-
propriate, for discrete data. A P value <0.05 was consid-
ered statistically significant. Statistical analysis was
performed with SPSS Statistics 17.0 (SPSS Inc., Illinois,
USA). Survival was calculated using the Kaplan–Meier
method and compared using the log-rank test. Survival
analysis was performed with JMP 9 (SAS Institute Inc.,
North Carolina, USA).
Results
During the study period, 53 patients – 21 males and 32
females – underwent TPE for advanced primary, recur-
rent, or suspected recurrent pelvic malignancies. Based
on pathology, patients were divided into a colorectal
(n = 36) and a non-colorectal (n = 17) group for analysis.
Demographics including age, gender, and number of
comorbidities were similar between the two groups
(Table 1). The median age of patients was 59 years
(range 40–80) in the colorectal group and 52 years
(range 38–79) in the non-colorectal group (P= 0.48).
There were sixteen males and twenty females in the
colorectal group, and five males and twelve females in
the non-colorectal group (P= 0.37). Estimated blood
loss, operative time, and length of stay were similar be-
tween the two groups. Mean length of stay was 17 days
overall, 15.8 (± 9.9) days in the colorectal group and
19.5 (± 11.5) days in the non-colorectal group (P= 0.23).
There was no significant difference in preoperative radi-
ation and intraoperative radiation treatment rates be-
tween the two groups. Twenty-eight patients (78%) in







Median age in years (range) 59 (40–80) 52 (38–79) 0.48
Gender M:F 16:20 5:12 0.37
Comorbidities 29 14 1.00
Mean (±SD) length
of stay (days)
15.8 ± 9.9 19.5 ± 11.5 0.23
Mean (±SD)
operative time (minutes)
603 ± 214 567 ± 165 0.53
Mean (±SD) estimated
blood loss (liters)
1.9 ± 1.2 2.6 ± 2.2 0.16
Preoperative radiation 28 (78%) 9 (53%) 0.11
Intraoperative radiation 16 (44%) 4 (24%) 0.23
Chemotherapy 20 (56%) 4 (24%) 0.04colorectal group underwent preoperative radiation treat-
ment (P= 0.23). A majority of patients were referred to
our institution for surgical intervention but received pre-
operative radiation at outside institutions. Preoperative
radiation doses were available for 23 of the 37 patients.
In the colorectal group, the 17patients for whom data
was available received a mean dose of 5265 cGy pre-
operatively. In the non-colorectal group, data was avail-
able for six of the nine patients. They received a mean
preoperative dose of 6990 cGy. Sixteen patients (44%) in
the colorectal group and four patients (24%) in the non-
colorectal group underwent intraoperative radiation
treatment (P= 0.11). Significantly more patients (n = 20,
56%) underwent chemotherapy in the colorectal group
compared with the non-colorectal group (n= 4, 24%)
(P= 0.04).
Overall, twelve patients (22.6%) had primary disease,
thirty-four patients (64.2%) had recurrent disease, and
seven patients (13.2%) had suspected recurrence or com-
plications from previous therapy. Within the colorectal
group, nine, twenty-two, and five patients had primary
disease, recurrent disease, and suspected recurrence, re-
spectively. Within the non-colorectal group, three,
twelve, and two patients had primary disease, recurrent
disease, and suspected recurrence, respectively. Table 2
shows the tumor pathology from all patients’ resections.
TPE was indicated for thirty-six colorectal, six gynecolo-
gic, and five urologic malignancies. Three patients had
leiomyosarcomas, two had anal cancer, and one patient
had benign disease requiring TPE for extensive infection
and inflammation.
Among both groups, there were nineteen R0 resec-
tions, twenty R1 resections, seven R2 resections, and
seven resections of suspected recurrence/complication
with no evidence of malignancy. Within the non-
colorectal group, ten patients (58.8%) underwent R1 re-
section, which was significantly higher than in the colo-
rectal group in which ten patients (27.8%) underwent R1
resection (P= 0.04) (Table 3). There was no significant
difference between the two groups with regards to R0
and R2 resections, and suspected recurrence. Table 4
compares complications between the two groups. There
was no difference in overall complications. The colorec-
tal group had statistically significantly more perineal













R0 15 (41.7%) 4 (23.5%) 0.23
R1 10 (27.8%) 10 (58.8%) 0.04
R2 6 (16.6%) 1 (5.9%) 0.41
Suspected recurrence/
complication
5 (13.9%) 2 (11.8%) 1.00
Colorectal
Non-colorectal 
Figure 1 Kaplan–Meier curve for survival in patients who
underwent TPE for colorectal cancer compared with patients
who underwent TPE for non-colorectal cancer (P= 0.002).
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patients, 17 underwent pelvic reconstruction with a rec-
tus abdominus myocutaneous flap, whereas 36 under-
went primary closure. There was no difference in
operative time, blood loss, length of stay or overall
wound complications between the two groups. In both
groups, 47% developed pelvic abscesses. In those
patients who underwent flap placement, two (12%)
developed perineal abscesses, compared with eight (22%)
in those who underwent primary closure (P= 0.47).
Within the colorectal group, 13 patients underwent re-
construction with a rectus abdominus myocutaneous
flap. Among the patients who underwent exenteration
for colorectal cancer, two of thirteen (15.4%) with flap
reconstruction developed a perineal abscess, compared
with eight of twenty-three patients (34.8%) who under-
went primary closure (P= 0.27).
There was no 30-day mortality in either group. The
median survival was 21.4 months in the colorectal group
and 6.9 months in the non-colorectal group (P= 0.002)
(Figure 1). Within the colorectal group, median survival
was 27.3 months for the R0 group, compared with
10.7 months for the R1 and R2 groups combined
(P= 0.03) (Figure 2). There was no significant difference
in median survival between patients undergoing TPE forTable 4 Morbidity and mortality following total pelvic









Overall 31 (86%) 13 (76%) 0.44
Wound infection 18 (50%) 6 (35%) 0.38
Wound dehiscence 8 (22%) 3 (18%) 1.00
Pelvic abscess 20 (56%) 5 (29%) 0.09
Perineal abscess 10 (28%) 0 (0%) 0.02
Enteric fistula 11 (31%) 3 (18%) 0.51
Sepsis 16 (44%) 5 (29%) 0.37
Bleeding 7 (19%) 1 (6%) 0.41
Respiratory failure 10 (28%) 2 (12%) 0.30
Deep venous thrombosis7 (19%) 1 (6%) 0.41
30-day morbidity 29 (81%) 11 (65%) 0.31
30-day mortality 0 (0%) 0 (0%) 1.00advanced primary colorectal cancer (25.2 months) and
patients undergoing TPE for recurrent colorectal cancer
(20.2 months).
Discussion
Brunschwig initially described the technique of TPE as a
palliative option for advanced cervical cancer [1]. The
procedure has also evolved to become a treatment op-
tion for locally advanced and recurrent pelvic malignan-
cies, including those of rectal, gynecologic, urologic, and
sarcomatous origin. Since the initial description, mortal-
ity rates have improved from greater than 30% [4-11] toR0
R1/2 
Figure 2 Kaplan–Meier curve for survival in patients who
underwent TPE for colorectal cancer, based on extent of
resection.
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consistent with other contemporary series, reflected in
the 30-day mortality rate of 0% for tumors of both colo-
rectal and non-colorectal origin. The decreased mortality
rates over the past 60 years may be due to a variety of
factors, including improved surgical technique, surgeon
experience, radiological imaging, neoadjuvant chemora-
diation therapy, anesthesia care, and perioperative care.
Our series demonstrated a statistically significant
improved survival for patients undergoing TPE for can-
cer of colorectal origin compared with patients undergo-
ing TPE for non-colorectal malignancies. Within the
non-colorectal group, there were three patients with pel-
vic sarcomas. These tumors are rare, with prognosis
based on the histologic grade and completeness of resec-
tion [25]. In our study, these patients lived for two, five,
and fifteen months, respectively. Their poor survival is
attributed to incomplete resections and high grade
histologies. A review of the literature showed Ferens-
child et al.’s group having a survival of 100% survival at
5 years [21]. Although they had a small number of
patients, all four had undergone R0 resection. Histolo-
gies for the patients were not reported. For patients with
sarcoma, chemotherapy does not provide any benefit, ra-
diation is limited due to toxicity to adjacent structures,
and surgery may be the only choice [25,26]. In a large
cohort of patients with retroperitoneal sarcomas, Lewis
et al. found that those who underwent incomplete resec-
tion (median survival of 18 months) had no difference in
survival from those whose disease was unresectable,
whereas those who underwent complete sarcoma resec-
tion had significantly improved outcome, with a median
survival of 103 months [25]. Therefore, extensive surgi-
cal resection by means of a TPE may be a good option
in patients with sarcoma, if they are able to undergo R0
resection.
In contrast to sarcomas, chemoradiation is the treat-
ment of choice for locally advanced primary cervical ma-
lignancies. Most TPEs performed for gynecological
cancer are performed for recurrent cervical cancer, [27-
29] because up to one third of patients with primary cer-
vical cancer have residual disease or develop recurrence
after chemoradiation therapy [30]. For central recur-
rences or large central primary tumors not responsive to
chemotherapy or radiation, radical surgery such as TPE
may be the only potential cure. Five-year survival rates
for patients who undergo TPE for recurrent cervical
cancer have been similar to those for patients who
undergo TPE for primary rectal cancer, with rates be-
tween 23% and 58% [21,27,28,31-36]. In our study popu-
lation, six patients had gynecological malignancies: one
vulvar, two vaginal, two cervical, and one endometrial.
As part of the non-colorectal group, their median sur-
vival was poor, which is probably due to four of the sixpatients having an R1 resection status. Only two patients
with gynecological malignancies underwent complete ex-
tirpation of tumor. This finding is consistent with the re-
mainder of the non-colorectal group, which had
significantly more patients with R1 resection status than
the colorectal group. Although not statistically signifi-
cant, there were fewer patients in the non-colorectal
group (23.5%) than in the colorectal group (41.7%) that
underwent complete tumor excision. This may explain
the worse overall survival for the non-colorectal group.
Within the heterogeneous non-colorectal group, the
number of patients with each histology was too small for
statistical analysis. This is consistent with much of the
literature, which remains sparse regarding TPE for un-
common indications such as recurrent endometrial can-
cer and urological malignancies [21,34,36-38]. However,
as with other recurrent pelvic malignancies, pelvic exen-
teration may be the only possible chance for cure. Bara-
kat et al.’s study of 44 patients who underwent pelvic
exenteration for recurrent endometrial cancer resulted
in a 5-year survival rate of 20%, with a major morbidity
rate of 80% [38]. Only 23 of these patients underwent
total exenteration, whereas the others underwent less ex-
tensive resection via anterior or posterior exenteration.
Future studies will require a larger number of patients
with sarcomas, gynecological malignancies, and uro-
logical malignancies in order to make definitive conclu-
sions regarding the use of TPE for treatment of these
particular malignancies.
The importance of resection status is demonstrated
both between the non-colorectal and colorectal groups,
as well as within the colorectal group. In patients who
underwent TPE for colorectal cancer, our results demon-
strated a significant survival advantage for patients with
R0 resection, with a median survival of 27.3 months,
compared with those who had R1/R2 resection with a
median survival of 10.7 months. This is consistent with
previous studies that have demonstrated that complete
resection is an important prognostic indicator of both
improved disease-free and overall survival [13,17,20,
21,39]. In patients who underwent pelvic exenteration
for primary advanced or recurrent pelvic tumors, Zoucas
et al. found that completeness of resection was the only
variable with a significant impact on survival [17]. Kray-
bill et al. [40] described a 5-year survival rate of 44% in
patients with negative margins, compared with a rate of
25% in patients with positive margins. Within our series,
although curative resection was attempted, seven
patients underwent R2 resection with evidence of gross
tumor remaining in the pelvis. With large tumors in the
pelvis requiring extensive dissection and mobilization,
combined with neoadjuvant chemotherapy and/or radi-
ation, it is sometimes difficult to determine whether
complete resection may be achieved until it is attempted.
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pelvic symptoms preoperatively that would have been
possible indications for palliative intervention, including
colovesical or enterovesical fistulas with chronic urinary
tract infections, colovaginal fistulas, and chronic pelvic
or perineal pain. In these circumstances, where complete
resection is not technically possible but patients have se-
vere pelvic symptomatology, palliative TPE, leaving gross
disease behind, would be indicated. Patients must be
well informed preoperatively about the risk of leaving
gross disease behind, even when TPE with curative in-
tent is performed.
Resection status may partially explain our results with
regards to survival for primary and recurrent colorectal
cancer. Our results did not demonstrate any difference
in survival between patients undergoing TPE for primary
advanced and recurrent colorectal tumors, with a me-
dian survival of 25.2 months and 20.2 months, respect-
ively. Other series, however, have demonstrated
improved survival for patients with cancers of primary
colorectal origin compared with recurrent, with 5-year
survival rates ranging from 30 to 77% for primary
[4,5,10,13-16,21,22,37,39,41-44] and from 6 to 31% for
recurrent disease [14,21,23,37,41,43-46]. Kecmanovic
et al. [37] found median survival rates following TPE for
primary and recurrent colorectal tumors were 50 months
and 31 months, respectively. Their study does not report
nodal status or resection status of the specimens. It is
possible that more patients with primary colorectal
tumors had node-negative disease and underwent
complete R0 resection, compared with those patients
with recurrent colorectal tumors, which could explain
the improved survival in the group with primary disease.
Law et al. described a 5-year survival rate of 64% in
patients who underwent TPE for primary colorectal can-
cer, and a rate of less than 11% in those who underwent
TPE for recurrent colorectal cancer. Only one of nine
patients with recurrent malignancy lived longer than
24 months, and this patient was alive at the last follow-
up at 47 months [13]. In their series, 27% of patients
with primary rectal cancer had node-positive disease and
100% underwent R0 resection, whereas only 44% of
patients in the recurrent rectal cancer group underwent
R0 resection. The low percentage of patients with node-
positive disease and the much improved R0 resection
status in patients with primary disease compared with
the patients with recurrent disease could explain the dif-
ference in survival between the two groups. Similarly,
Ferenschild et al. reported 5-year survival rates of 66%
and 8% for patients who underwent TPE for primary
and recurrent rectal cancer, respectively [21]. R0 resec-
tion status was reported in a higher proportion of
patients with primary disease (85%) than with recurrent
disease (65%). The resection status may account for theimproved survival in primary disease. By contrast, within
our series, we did not find a significantly improved sur-
vival in patients undergoing TPE for primary disease
compared with recurrent disease. A high proportion of
patients with primary tumors (67%) had node-positive
disease. In addition, an R0 resection was achieved in
67% and 41% of patients with primary and recurrent
colorectal disease, respectively. The similarity in survival
rates between those with primary and those with recur-
rent colorectal disease in our series may be due to this
high percentage of patients with primary disease who
were node-positive, and the similar percentages of
patients who underwent R0 resection for primary and
recurrent colorectal disease.
The group of seven patients who underwent TPE for
suspected recurrence or complications from radiation
therapy is an interesting subset of patients. Six of the
seven had undergone preoperative radiation treatment
to the pelvis. Five of these, as well as the one patient
who did not undergo radiation, underwent chemother-
apy prior to surgery. Of these patients, four had frozen
section analysis that showed no evidence of malignancy.
The other three patients had some type of fistula prior
to surgery: enterocutaneous, colovaginal, or colovesical.
In two patients, permanent specimen analysis revealed
extensive necrosis with no viable tumor, consistent with
treatment effect. The remaining pathological analyses
showed densely fibrotic tissue or necrotic tissue. Al-
though no viable tumor was found on pathological ana-
lysis, it is obvious that their previous malignancy and
their preoperative treatment – chemotherapy, radiation,
surgery, or a combination – contributed to the patients’
symptoms, with patients having fibrotic areas with asso-
ciated fistulas, hydronephrosis, or other obstruction.
Two of these patients died a year postoperatively, one
died at two years, and the remainder are still alive two,
four, six, and seven years postoperatively. In this group
of patients, all had severe preoperative pelvic symptom-
atology; therefore, although their pathology was consid-
ered benign, or at least without viable tumor, their
extensive symptomatology would have been the indica-
tion for TPE.
Morbidity rates were substantial among all patients,
with similar rates of 86% and 76% in the colorectal and
non-colorectal groups, respectively. These rates are high
compared with those reported in the literature, which
ranged from 13 to 78% [4,10-16,18-23]. However, our
high rates can be explained by our stringent definition of
morbidity, which included any deviation from the
expected postoperative course, including anything that
required longer hospitalization or any type of interven-
tion. Rates of wound infection and wound dehiscence
were similar between the groups. In the colorectal
group, 50% of patients had wound infections compared
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cence occurred in 22% of colorectal patients and in 18%
of non-colorectal patients. These accounted for the ma-
jority of the complications in both groups. There were
significantly more perineal abscesses and a trend toward
more pelvic abscesses in the colorectal group than in the
non-colorectal group. The rate of pelvic abscesses in the
non-colorectal group is consistent with gynecologic lit-
erature [27]. The comparatively higher abscess rate in
the colorectal group is probably due to the location of
the tumors and the extensive perineal and pelvic ma-
nipulation of the often irradiated, inflamed, or fixed
bowel that is required to dissect and extirpate these
tumors, with potential bacterial contamination from
bowel contents. Within our study group of 53 patients,
17 underwent pelvic reconstruction with rectus abdomi-
nus myocutaneous flaps to assist with wound healing.
Thirteen of these patients were within the colorectal
group. There was no difference in complications be-
tween those who had flaps and those who underwent
primary closure. There were fewer perineal abscesses in
those with flaps, although this was not statistically sig-
nificant. Among those who underwent TPE for colorec-
tal malignancy, there were fewer patients who developed
perineal abscesses with flap placement compared with
those who had primary closure, but this also was not
statistically significant. A larger study may demonstrate
an advantage to using rectus abdominus myocutaneous
flaps for closure of pelvic wounds following TPE for
colorectal malignancy.
This study is limited by its retrospective nature, lead-
ing to the inability to establish a cause and effect rela-
tionship. It is also limited due to its small sample size.
Within the non-colorectal cancer group, there were too
few patients with each type of histology to make conclu-
sions about patients who undergo TPE for any other
particular type of pelvic malignancy, such as cervical
cancer, endometrial cancer, or bladder cancer. A pro-
spective study including a larger sample size of patients
who have each of the various other pelvic cancers would
allow us to make conclusions related to their respective
malignancies. It would also be beneficial to include an
assessment of quality of life, especially because our
results showed such a short median survival for patients
in the non-colorectal cancer group.
Conclusions
Patients who undergo TPE for colorectal cancer have
improved survival compared with patients who undergo
this extensive surgery for pelvic malignancies of other
origins. The results show improved survival for colorec-
tal cancer patients with complete R0 resection of tumor.
Although the procedure is still associated with signifi-
cant morbidity, mortality rates are acceptable. Carefulpatient selection can optimize outcomes in patients
undergoing TPE. Future studies may seek to predict
which colorectal patients could potentially undergo TPE
with successful R0 resection, leading to the best overall
survival benefit from this procedure.
Abbreviations
CT: Computed tomography; PET: Positron emission tomography; TPE: Total
pelvic exenteration.
Competing interests
The authors have no competing interests to declare.
Authors’ contributions
MK participated in conception of the study, data collection and analysis, and
drafted the manuscript. RC participated in conception of the study, data
collection and analysis, and helped draft the manuscript. DA participated in
conception of the study. EM participated in conception of the study, design
and coordination, data analysis, and helped draft the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
There is no source of funding.
Author details
1Division of Surgical Oncology, Department of Surgery, Arthur G. James
Cancer Hospital and Richard J. Solove Research Institute and Comprehensive
Cancer Center, Wexner Medical Center, The Ohio State University, 395 W
12th Ave, Room 654, Columbus, OH 43210, USA. 2Division of Surgical
Oncology, NJMS-UH Cancer Center, Newark, NJ 07103, USA. 3Columbus
Surgical Specialists, Riverside Methodist Hospital, Columbus, OH 43214, USA.
Received: 4 February 2012 Accepted: 15 June 2012
Published: 15 June 2012
References
1. Brunschwig A: Complete excision of pelvic viscera for advanced
carcinoma; a one-stage abdominoperineal operation with end
colostomy and bilateral ureteral implantation into the colon above the
colostomy. Cancer 1948, 1:177–283.
2. Bricker EM: Bladder substitution after pelvic evisceration. Surg Clin North
Am 1950, 30:1511–1521.
3. Carter MF, Dalton DP, Garnett JE: Simultaneous diversion of the urinary
and fecal streams utilizing a single abdominal stoma: the double-
barreled wet colostomy. J Urol 1989, 141:1189–1191.
4. Boey J, Wong J, Ong GB: Pelvic exenteration for locally advanced
colorectal carcinoma. Ann Surg 1982, 195:513–518.
5. Lopez MJ, Kraybill WG, Downey RS, Johnston WD, Bricker EM: Exenterative
surgery for locally advanced rectosigmoid cancers. Is it worthwhile?
Surgery 1987, 102:644–651.
6. Brintnall ES, Flocks RH: En masse pelvic viscerectomy with
ureterointestinal anastomosis. AMA Arch Surg 1950, 61:851–868.
7. Falk RE, Moffat FL, Makowka L, Konn G, Bulbul MA, Rotstein LE, Bruce AW:
Pelvic exenteration for advanced primary and recurrent
adenocarcinoma. Can J Surg 1985, 28:539–541.
8. Lopez MJ, Standiford SB, Skibba JL: Total pelvic exenteration. A 50-year
experience at the Ellis Fischel Cancer Center. Arch Surg 1994, 129:390–
396.
9. Lindsey WF, Wood DK, Briele HA, Greager JA, Walker MJ, Bork J, Das Gupta
TK: Pelvic exenteration. J Surg Oncol 1985, 30:231–234.
10. Eckhauser FE, Lindenauer SM, Morley GW: Pelvic exenteration for
advanced rectal carcinoma. Am J Surg 1979, 138:412–414.
11. Ledesma EJ, Bruno S, Mittelman A: Total pelvic exenteration in colorectal
disease: a 20-year experience. Ann Surg 1981, 194:701–703.
12. Hafner GH, Herrera L, Petrelli NJ: Morbidity and mortality after pelvic
exenteration for colorectal adenocarcinoma. Ann Surg 1992, 215:63–67.
13. Law WL, Chu KW, Choi HK: Total pelvic exenteration for locally advanced
rectal cancer. J Am Coll Surg 2000, 190:78–83.
Kuhrt et al. World Journal of Surgical Oncology 2012, 10:110 Page 8 of 8
http://www.wjso.com/content/10/1/11014. Jimenez RE, Shoup M, Cohen AM, Paty PB, Guillem J, Wong WD:
Contemporary outcomes of total pelvic exenteration in the treatment of
colorectal cancer. Dis Colon Rectum 2003, 46:1619–1625.
15. Chen HS, Sheen-Chen SM: Total pelvic exenteration for primary local
advanced colorectal cancer. World J Surg 2001, 25:1546–1549.
16. Shirouzu K, Isomoto H, Kakegawa T: Total pelvic exenteration for locally
advanced colorectal carcinoma. Br J Surg 1996, 83:32–35.
17. Zoucas E, Frederiksen S, Lydrup ML, Mansson W, Gustafson P, Alberius P:
Pelvic exenteration for advanced and recurrent malignancy. World J Surg
2010, 34:2177–2184.
18. Jakowatz JG, Porudominsky D, Riihimaki DU, Kemeny M, Kokal WA, Braly PS,
Terz JJ, Beatty JD: Complications of pelvic exenteration. Arch Surg 1985,
120:1261–1265.
19. Saito N, Koda K, Takiguchi N, Oda K, Ono M, Sugito M, Kawashima K, Ito M:
Curative surgery for local pelvic recurrence of rectal cancer. Dig Surg
2003, 20:192–200.
20. Yamada K, Ishizawa T, Niwa K, Chuman Y, Aikou T: Pelvic exenteration and
sacral resection for locally advanced primary and recurrent rectal cancer.
Dis Colon Rectum 2002, 45:1078–1084.
21. Ferenschild FT, Vermaas M, Verhoef C, Ansink AC, Kirkels WJ, Eggermont
AM, de Wilt JH: Total pelvic exenteration for primary and recurrent
malignancies. World J Surg 2009, 33:1502–1508.
22. Ike H, Shimada H, Yamaguchi S, Ichikawa Y, Fujii S, Ohki S: Outcome of
total pelvic exenteration for primary rectal cancer. Dis Colon Rectum 2003,
46:474–480.
23. Ike H, Shimada H, Ohki S, Yamaguchi S, Ichikawa Y, Fujii S: Outcome of
total pelvic exenteration for locally recurrent rectal cancer.
Hepatogastroenterology 2003, 50:700–703.
24. Chokshi RJ, Kuhrt MP, Schmidt C, Arrese D, Routt M, Parks L, Bahnson R,
Martin EW Jr: Single institution experience comparing double-barreled
wet colostomy to ileal conduit for urinary and fecal diversion. Urology
2011, 78:856–862.
25. Lewis JJ, Leung D, Woodruff JM, Brennan MF: Retroperitoneal soft-tissue
sarcoma: analysis of 500 patients treated and followed at a single
institution. Ann Surg 1998, 228:355–365.
26. Lewis JJ, Benedetti F: Adjuvant therapy for soft tissue sarcomas. Surg
Oncol Clin North Am 1997, 6:847–862.
27. Sharma S, Odunsi K, Driscoll D, Lele S: Pelvic exenterations for
gynecological malignancies: twenty-year experience at Roswell Park
Cancer Institute. Int J Gynecol Cancer 2005, 15:475–482.
28. Berek JS, Howe C, Lagasse LD, Hacker NF: Pelvic exenteration for recurrent
gynecologic malignancy: survival and morbidity analysis of the 45-year
experience at UCLA. Gynecol Oncol 2005, 99:153–159.
29. Goldberg JM, Piver MS, Hempling RE, Aiduk C, Blumenson L, Recio FO:
Improvements in pelvic exenteration: factors responsible for reducing
morbidity and mortality. Ann Surg Oncol 1998, 5:399–406.
30. Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 1999,
49:33–64.
31. Soper JT, Berchuck A, Creasman WT, Clarke-Pearson DL: Pelvic exenteration:
factors associated with major surgical morbidity. Gynecol Oncol 1989,
35:93–98.
32. Averette HE, Lichtinger M, Sevin BU, Girtanner RE: Pelvic exenteration: a
15-year experience in a general metropolitan hospital. Am J Obstet
Gynecol 1984, 150:179–184.
33. Lopez MJ: Exenterative pelvic surgery. Surg Clin North Am 1994, 3:197–418.
34. Lawhead RA Jr, Clark DG, Smith DH, Pierce VK, Lewis JL: Pelvic exenteration
for recurrent or persistent gynecologic malignancies: a 10-year review of
the Memorial Sloan-Kettering Cancer Center experience (1972–1981).
Gynecol Oncol 1989, 33:279–282.
35. Morley GW, Hopkins MP, Lindenauer SM, Roberts JA: Pelvic exenteration,
University of Michigan: 100 patients at 5 years. Obstet Gynecol 1989,
74:934–943.
36. Roos EJ, Van Eijkeren MA, Boon TA, Heintz AP: Pelvic exenteration as
treatment of recurrent or advanced gynecologic and urologic cancer. Int
J Gynecol Cancer 2005, 15:624–629.
37. Kecmanovic DM, Pavlov MJ, Kovacevic PA, Sepetkovski AV, Ceramic MS,
Stamenkovic AB: Management of advanced pelvic cancer by
exenteration. Eur J Surg Oncol 2003, 29:743–746.
38. Barakat RR, Goldman NA, Patel DA, Venkatraman ES, Curtin JP: Pelvic
exenteration for recurrent endometrial cancer. Gynecol Oncol 1999,
75:99–102.39. Moriya Y, Akasu T, Fujita S, Yamamoto S: Total pelvic exenteration with
distal sacrectomy for fixed recurrent rectal cancer in the pelvis. Dis Colon
Rectum 2004, 47:2047–2054.
40. Kraybill WG, Lopez MJ, Bricker EM: Total pelvic exenteration as a
therapeutic option in advanced malignant disease of the pelvis. Surg
Gynecol Obstet 1988, 166:259–263.
41. Hafner GH, Herrera L, Petrelli NJ: Patterns of recurrence after pelvic
exenteration for colorectal adenocarcinoma. Arch Surg 1991, 126:
1510–1513.
42. Liu SY, Wang YN, Zhu WQ, Gu WL, Fu H: Total pelvic exenteration for
locally advanced rectal carcinoma. Dis Colon Rectum 1994, 37:172–174.
43. Pawlik TM, Skibber JM, Rodriguez-Bigas MA: Pelvic exenteration for
advanced pelvic malignancies. Ann Surg Oncol 2006, 13:612–623.
44. Chokshi RJ, Abdel-Misih S, Bloomston M: Surgical management of
colorectal cancer: a review of the literature. Ind J Surg 2009, 71:350–355.
45. Yeung RS, Moffat FL, Falk RE: Pelvic exenteration for recurrent and
extensive primary colorectal adenocarcinoma. Cancer 1993, 72:1843–1858.
46. Wanebo HJ, Antoniuk P, Koness RJ, Levy A, Vezeridis M, Cohen SI, Wrobleski
DE: Pelvic resection of recurrent rectal cancer: technical considerations
and outcomes. Dis Colon Rectum 1999, 42:1438–1448.
doi:10.1186/1477-7819-10-110
Cite this article as: Kuhrt et al.: Retrospective review of pelvic
malignancies undergoing total pelvic exenteration. World Journal of
Surgical Oncology 2012 10:110.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
